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ABSTRACT
Purpose To investigate the destruction of clinically-relevant
bacteria within biofilms via the sustained release of the
antibiotic tetracycline from zein-based electrospun polymeric
fibrous matrices and to demonstrate the compatibility of such
wound dressing matrices with human skin cells.
Methods Zein/PCL triple layered fibrous dressings with
entrapped tetracycline were electrospun. The successful
entrapment of tetracycline in these dressings was validated.
The successful release of bioactive tetracycline, the destruction
of preformed biofilms, and the viability of fibroblast (FEK4)
cells were investigated.
Results The sustained release of tetracycline from these ma-
trices led to the efficient destruction of preformed biofilms
from Staphylococcus aureus MRSA252 in vitro, and of
MRSA252 and ATCC 25923 bacteria in an ex vivo pig skin
model using 1×1 cm square matrices containing tetracycline
(30 μg). Human FEK4 cells grew normally in the presence of
these matrices.
Conclusions The ability of the zein-based matrices to destroy
bacteria within increasingly complex in vitro biofilm models
was clearly established. An ex vivo pig skin assay showed that
these matrices, with entrapped tetracycline, efficiently kill bac-
teria and this, combined with their compatibility with a hu-
man skin cell line suggest these matrices are well suited for
applications in wound healing and infection control.
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ABBREVIATIONS
3L Triple-layered
CBM Colony Biofilm Model
DCM Dichloromethane
MIC Minimum inhibitory concentration
MTP 96-Well Microtiter Plate
OD Optical density
TFE 2,2,2-Trifluoroethanol
TSB Tryptone Soya broth
TSB-GN Tryptone Soya broth containing 0.5%
glucose and 3% NaCl
INTRODUCTION
Electrospinning is an established technique for the fabrication
of nanoscale fibres (1–3). It continues to be studied extensively
due to its various advantages such as high surface-to-volume
ratio, tuneable porosity, and ease of surface functionalization.
Indeed, the resulting fibres are extremely useful for applica-
tions in tissue engineering, drug delivery, and wound dress-
ings. This is an area with huge potential for controlled release
research. As electrospun fibres mimic the extracellular matrix
(ECM) of tissues in terms of scale and morphology, there is the
potential for them to be used as scaffolds. Taken together with
their physical and chemical properties, electrospun scaffolds
are being evaluated in various cellular studies, in sustained
drug delivery, and as potential wound dressings (1–3). The
localized and controlled drug delivery that might be achieved
from electrospun micro/nanofibres could be applied in new
treatments for burns or biomedical applications related to
chronic wounds (1–3).
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Burns and chronic wounds, such as diabetic ulcers, are hard
to heal and require prolonged treatment due to a number of
clinical complications (4, 5). There is an increasing interest in
the topical application of antimicrobials to overcome the prob-
lems associated with the low levels of antibiotic in the granulat-
ing tissue (5). In future wound treatments, there may also be a
desire to leave dressings on for extended periods, as this will
minimise damage to newly formed tissue. However, current
application of topical antimicrobials requires daily or twice-
daily changes of the dressing, leading to patient discomfort as
well as being time consuming and costly. There is therefore a
considerable interest in dressings that allow the controlled re-
lease of antibiotics (6).
Biofilms are prevalent in nature and appear to be associated
with the majority of infections, e.g. wound infections, catheter-
linked infections, endocarditis, dental caries, and cystic fibrosis
(7). Microbial communities infect chronic wounds and they
often involve biofilms rather than planktonic cells (8–10). A
particular problem of bacteria within biofilms is that they are
significantlymore resistant to antibiotics compared to their free-
floating planktonic counterparts (11). Indeed, as a result of this
increased resistance of biofilms to treatment by antibacterial
agents, it is important to test the controlled release of an anti-
biotic matrix against bacterial biofilms. In wounds that require
antibiotic treatment, localized antibiotic delivery systems may
overcome the problems associated with the low antibiotic levels
in the granulating tissue (5). We have recently developed for-
mulations in which tetracycline (Tet) hydrochloride has been
successfully incorporated in multi-layered electrospun micro/
nanofibre matrices of zein and poly-ε-caprolactone (PCL) (12).
We now report assays designed to test antibacterial activity
achieved in a series of models of selected wound-associated
biofilms of increasing complexity.
Alpha-zein is a corn (maize) protein containing a high per-
centage of non-polar amino acids with the ability to form ag-
gregates and entrap solutes, such as drugs and amino acids.
However, there are only a few papers, and those all recently
published (12–16), reporting the incorporation of antibiotics
within electrospun zein. Antimicrobial (chitosan) electrospun
zein fibre structures provide a new strong antimicrobial
ultrathin-structured system (13). Also, in order to develop bio-
compatible nanofibrous membranes for wound healing, the
coelectrospinning of two proteins, zein and collagen, in aqueous
acetic acid solution, was investigated where the combination
with zein improved the electrospinning of collagen. The drug
berberine was then incorporated in situ into the electrospun
nanofibrous membrane, with little effect on fibre morphology
and cell viability, in order to investigate its controlled release
and antibacterial activity. Wound healing by these berberine
releasing nanofibre membranes was examined in vivo using fe-
male Sprague Dawley rats and histology (14).
Luzardo-Alvarez and co-workers have used NMR spec-
troscopy to detect binding interactions and measure affinity
between zein and three different drugs: indomethacin, and the
antibiotics amoxicillin and Tet. Such protein-drug interac-
tions show that zein is promising for the rational design of
drug delivery vehicles (15). Luzardo-Alvarez et al. have also
reported that treatment with Tet antibiotics within the peri-
odontal pocket against Staphylococcus aureus bacterial infections
represents a useful and adjunctive tool to conventional thera-
py for healing and teeth preservation. Thus, a two-polymer
system of zein and PLGA has been developed as a bio-
degradable implant (16). Sustained release of Tet was
obtained, and the proportion of zein in the inserts had
a significant impact on the antibiotic release. Indeed, an
effective release of Tet from the inserts against S. aureus
achieved over 30 days of controlled delivery, and hence
this may be suitable for the intra-pocket delivery of an-
timicrobial agents in the treatment of periodontitis (16).
In this paper, we report the incorporation of Tet in
electrospun micro/nanofibre zein/PCL triple layers (3L) and
its controlled release from these matrices (12). We show excel-
lent antibiotic activity resulting in the destruction of clinically-
relevant different S. aureus bacterial strains that are efficient
biofilm formers, including activity against MRSA252, a rep-
resentative of a lineage (EMRSA-16) that is endemic in UK
hospitals (17). In particular, we investigate the biological ac-
tivity of sustained release Tet in an ex vivo pig skin model
relevant for wound dressing research and, for the first time,
we report on the compatibility of such zein/PCL wound
dressing matrices with human fibroblast (FEK4) skin cells.
MATERIALS AND METHODS
Materials
Zein was purchased fromAcrosOrganics. Poly-ε-caprolactone
(PCL) (Mn 70 000–90 000), tetracycline (Tet) hydrochloride,
other antibiotics and other chemicals, solvents, and mem-
brane filters for microscopy (polycarbonate discs, pore
size 0.2 μm, diameter 13 mm) were purchased from
Sigma-Aldrich. Müller-Hinton (MH) agar, MH broth,
Tryptone Soya broth (TSB), and antimicrobial tetracy-
cline hydrochloride susceptibility test discs were pur-
chased from Oxoid. Luria-Bertani (LB) broth, Costar
polystyrene 96-well plates (f lat bottom, volume
0.36 mL, well diameter 7 mm), and gene frames (1×
1 cm) were purchased from Fisher. Crystal violet 1%
was purchased from PRO-LAB Diagnostics. Filter discs
were cut from Whatman 3MM Chr cellulose chroma-
tography paper (0.34 mm thickness). The bacterial
strains used in this study were S. aureus MRSA252 (17)
and S. aureus ATCC 25923; these strains were main-
tained on Tryptone Soy Agar (Oxoid) plates.
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Preparation and Characterisation of Electrospun
Matrices of Zein or Zein/PCL
Triple-layered (3L) matrices were prepared as recently report-
ed (12). Zein solution was prepared at 30% (w/v) in a 1:1 (v/v)
mixture of 2,2,2-trifluoroethanol (TFE):dichloromethane
(DCM). Tet was dissolved in TFE at 5% (w/w) of the weight
of zein. For blended matrices of zein and PCL, zein was dis-
solved at 20% and PCL at 10% in 1:1 (v/v) TFE:DCM,
resulting in solutions with a total polymer concentration of
30% (w/v) with Tet (dissolved in TFE) again incorporated at
5% of the weight of the polymer. The polymer solution was
loaded into a syringe and electrospun at 18 kV and a flow rate
of 0.75 mL/h, with a distance between the tip of the needle
and the collector of 13 cm. The flow rate was controlled by a
syringe infusion pump (Cole Parmer, 230 VAC). The collec-
tor was constructed of two parallel metal electrodes covered
with aluminium foil. 3L matrices consist of outer layers free of
drug and an inner layer with Tet 5% of the weight of the
polymer. To make these matrices, each polymer solution
was electrospun using a fixed volume for each layer (1 mL
for the outer layers and 0.5 mL for the inner layer) in a
layer-by-layer manner. Two matrices were produced: triple-
layered zein with Tet in the middle layer (zein 3L) and triple-
layered zein/PCL with Tet in the middle layer (zein/PCL
3L). Three replicates of each formulation were fabricated.
The viscosity of the electrospinning solutions was measured
using a Bohlin high resolution C-VOR 200 Rheometer
equipped with plate accessory using the spindle type CP4/
40 maintained at 25°C. The shear rate was 50–100 Pa for
the zein solution and 100–500 Pa for the zein/PCL solution.
The surface morphology of electrospunmatrices was observed
by scanning electron microscopy (SEM) on matrices cut into
small cm2 sized pieces (12).
In Vitro Drug Release
The electrospun matrices were cut into 1.2×1.2 cm squares
and, to minimise the effect of drug release from the edges, the
samples were adhered to plastic coverslips using a gene frame
to give an available release surface of 1 cm2. Samples were
placed under sink conditions in plastic vials containing phos-
phate buffered saline (PBS, 5 mL, pH 7.4) and incubated at
37°C. At set time-points, the PBS was replaced and Tet re-
lease was determined in the sampled buffer by measuring its
UV absorbance at λ=360 nm against a standard curve.
Cumulative Tet release was determined by comparing
the mass released at each time point with the theoretical
mass of Tet encapsulated in each sample. Triplicate
samples were examined for each formulation and the
experiment was performed three times with indepen-
dently electrospun mats (12).
MIC Planktonic Bacteria Assay
Minimum inhibitory concentration (MIC) values against
planktonic bacterial cells were determined with a
microdilution broth method using MH Broth as previously
described (18).
96-Well Microtiter Plate (MTP) Biofilm Assay
The effect of antibiotics on biofilms of S. aureus
MRSA252 was tested as we have recently described
(19–21), with minor modifications. Briefly, these bacterial
cells were cultured (15 h) in TSB containing 0.5% glu-
cose and 3% NaCl (TSB-GN) and diluted 20-fold. The
diluted bacterial suspension (200 μL/well) was dispensed
into a polystyrene 96-well plate, and the plates were in-
cubated for 24 h at 37°C on a 3-dimensional plate rota-
tor (40 rpm). The cell suspension was removed and the
biofilms were washed carefully with sterile PBS (200 μL).
The effectiveness across a panel of antibiotics was then
tested on preformed biofilms on the same plate, therefore
on the same day and under the same conditions. To test
the antibiotics, 200 μL fresh TSB-GN (control wells) or
TSB-GN containing the appropriate concentration of an-
tibiotic (50 μg/mL) was added to preformed (24 h)
biofilms, and the plates were then incubated for a further
24 h. After this, non-adherent cells were removed, and
the biofilms were washed with sterile PBS (3×200 μL/
well). The plates were dried (1 h at 20°C) and biofilms
were then stained with crystal violet solution (1% w/v).
After 15 min, the excess of crystal violet was removed,
plates were washed briefly with water (4×250 mL), and
the crystal violet was dissolved in aqueous acetic acid
(30% v/v in distilled water). The absorbance, representa-
tive of the amount of biofilm remaining after treatment,
was measured at λ=595 nm (A595) using a FLUOstar
Omega spectrophotometer (BMG LABTECH, UK).
To test the effectiveness of Tet loaded electrospunmatrices,
fresh TSB-GN (200 μL) was added to preformed (24 h)
biofilms of S. aureus MRSA252, and then matrices (6 mm di-
ameter) or Tet solution were added to each well in 7 groups,
with 3 replicates: matrices containing 30 μg Tet (zein 3L,
zein/PCL 3L), matrices containing no Tet (single layer zein
no Tet, zein/PCL no Tet), Tet solution (30 μg/well), a nega-
tive control (media+Tet solution 30 μg/well, in wells without
biofilm), and a positive control (wells with biofilm, only fresh
medium added). Plates were incubated again for 24 h at 37°C.
The next day, the same discs were transferred to newly
preformed biofilms, incubated for 24 h at 37°C, and this
was repeated a third time. After each treatment, the bacterial
suspension was removed and the biofilms were washed,
stained, and analysed as above (19–21).
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Colony Biofilm Model (CBM)
The effect of Tet loaded electrospun matrices on biofilms was
tested in the CBM as recently described (20, 22), with minor
modifications. S. aureus MRSA252 was cultured (15 h) in TSB-
GN, and diluted to an OD at 600 nm of 0.4–0.6. Three sterile
13 mm polycarbonate discs were placed on the surface of TSB
agar plates and aliquots (50 μL) from the diluted bacterial sus-
pension were spotted on to each disc. Inoculated discs were in-
cubated for 72 h at 37°C to allow formation of the biofilm. The
polycarbonate discs were carefully transferred to new agar plates
with sterile forceps on a daily basis. On the fourth day, the discs
were covered with zein 3L or zein/PCL 3L (13 mm diameter).
The third polycarbonate disc was left without any treatment.
Before covering the discs with the 3L matrices, the surface of
the biofilms was wetted with TSB (10 μL) and, after coverage,
another 20 μL of broth was applied on top of the matrices. The
plates were then incubated again at 37°C for 24 h. Each disc was
then transferred to a tube containing TSB (5 mL) and kept cool
on ice during the experiment. The tubes were vortexed exten-
sively (~5 min) in order to disrupt mechanically the biofilms and
detach the bacteria from the discs. Suspended cells were then
serially diluted to 10−7 in broth, and aliquots (10 μL) of 10−4,
10−5, 10−6, and 10−7 dilutions were spotted on TSB agar plates,
to determine the colony forming units (CFU)/mL using the
Miles-Misra method (23). The plates were incubated at 37°C
for 24 h and the numbers of CFU were counted. The number
of CFU/disc was determined using the following formula:
CFU/disc = CFU counted × dilution factor × 100×5; this
was then normalised by the number of CFU/biofilm disc.
Ex Vivo Pig Skin Infection Model
The routine preparation of the pig skin followed this procedure.
Thawed pig skin (ex-abattoir, stored for weeks frozen) was
epilated with a dry razor, stripped with a tape 10-times to re-
move the upper dead layers, and finally cut into 1×1 cm2 pieces.
The pieces were sterilised firstly by immersing in 70% ethanol
for 20 min, dried for 20 min in a biosafety cabinet, followed by
soaking in a solution of antibiotics for 16 h (kanamycin sulfate
20 μg/mL and ampicillin 50 μg/mL). On the day of the
experiment, a cut 0.9 cm long was created along the skin to
reach the epidermal layer using a sharp knife. The cut pig skin
squares were then placed on TSB agar plates prepared with
antibiotics (kanamycin sulfate 20 μg/mL and ampicillin
50 μg/mL).
S. aureus MRSA252 or ATCC 25923 were cultured (15 h)
in TSB-GN. Inoculation was with an aliquot (20 μL) of bac-
terial suspension applied to the epidermal side of the skin and
spread uniformly. The inoculated skin pieces were incubated
for 5 days at 37°C in a humidified chamber. Every day the
pieces were transferred to a new agar plate. Four pig skin
pieces were used in each repeat. On day 5, the pig skin pieces
were covered with zein 3L, zein/PCL 3L (1 cm2), or a filter
paper loaded with 30 μg Tet. A fourth pig skin piece was left
untreated. Before covering the pig skin pieces with the 3L
matrices, the surface of the biofilms was wetted with TSB-
GN (10 μL) and, after coverage, another 20 μL of broth was
applied on top of thematrices. The plates were then incubated
again at 37°C for 24 h. Each skin piece was then transferred to
a tube containing MH broth (5 mL) and kept cool on ice
during the experiment. The tubes were vortexed extensively
(~5 min) in order to detach mechanically the bacteria from
the skin. Suspended cells were then serially diluted to 10−7 in
broth, and aliquots (10 μL) of 10−4, 10−5, 10−6, and 10−7
dilutions were spotted on TSB-GN agar plates, to determine
the colony forming units (CFU)/mL using the Miles-Misra
method (23). The plates were incubated at 37°C for 24 h
and the numbers of CFU were counted. The number of
CFU/skin piece was determined using the above formula; this
was then normalised by the number of CFU/untreated skin
piece.
Cell Viability Test (MTS Assay)
Single layer zein and zein/PCL electrospun matrices contain-
ing 5% Tet were punched into 6 mm diameter discs and fixed
to the bottom of the wells of 96-well plates using pieces of gene
frame. FEK4 cells are passage-dependent human primary fore-
skin fibroblasts. They were routinely cultured in Earle’s modi-
fied minimum essential medium supplemented with 10% fetal
calf serum (heat-inactivated at 56°C for 45 min before use) and
50 IU/mL of penicillin and streptomycin, and maintained at
37°C in a humidified incubator with 5% CO2. FEK4 cells
between passage 11 and 17 were seeded in each well at 750
cells/100 μL and incubated for 3 days before the relative cell
number was assessed using the MTS assay. On the day of the
assay, MTS reagent (20 μL) was added to each well and incu-
bated for another 4 h at 37°C. After incubation, culture medi-
um (50 μL) was then transferred from each well to a new 96-
well plate and the absorbance of the solutions measured at
490 nm (n=3, in triplicate). Tet solution alone and cells seeded
directly on the tissue culture plastic wells were used as controls.
Student’s t-tests were performed using Microsoft Excel to
determine any statistically significant differences between the
formulations and the commercially available Tet filter discs;
p<0.05 is considered to be significant.
RESULTS AND DISCUSSION
96-Well Microtiter Plate (MTP) Assay of Antibiotic
Activity in Destroying MRSA Biofilms
A now well-established consequence of the formation and
maturation of microbial biofilms is increased resistance to
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antibiotics and hence their failure in therapy (24). In part, this
occurs by preventing access of the antibiotics to their sites of
action, together with other mechanisms still not completely
understood (24). We have tested a range of clinically impor-
tant antibiotics against preformed MRSA252 biofilms using
the Microtitre Plate (MTP) assay model.
The data show (Fig. 1) that vancomycin, the glycopeptide
often named as the antibiotic of last resort for certain multi-
drug resistant Gram-positive infections, and gentamicin are
only weakly active against this S. aureus strain once biofilms
have formed. However, tetracycline (Tet), used for the treat-
ment of skin infections, and chloramphenicol, less widely used
except in over the counter (OTC) eye-drops against conjunc-
tivitis, were active removing ~50% of the biofilms (Fig. 1). In
addition, we have also assayed the MIC values of these anti-
biotics against planktonicMRSA252 bacterial cells. TheMIC
values are: gentamicin 1 μg/mL; Tet 0.25 μg/mL; vancomy-
cin 0.25 μg/mL; chloramphenicol 16 μg/mL (18). These
MIC values are considerably (200-fold for Tet) lower than
the concentrations used (Fig. 1) in destroying MRSA biofilms.
Gentamicin is known to be less active against intracellular
bacteria (25, 26), but that is not relevant in the MTP assay
where the bacteria are adhered to polystyrene wells. The ac-
tivity of these antibiotics against planktonic cells is significantly
higher, and the lower activity is due to the biofilm state of the
bacteria. Lack of biological activity against biofilms is due to a
number of factors, including penetration of the antibiotic into
the biofilm, and the low rates of cell growth in a biofilm as
many cells in a biofilm are in a semi-dormant state (27).
With regard to potential wound dressings, we have there-
fore focussed our research on the sustained and controlled
release of Tet in in vitro and ex vivo models of increasing com-
plexity with bacterial targets where biofilms are known to be a
clinical problem. Interestingly, Tet is normally considered
bacteriostatic, yet at the concentrations used here it results in
the removal of the biofilms. However, it should be noted that
at concentrations > 0.3 μg/mL Tet was shown to be bacteri-
cidal for S. aureus (28). The concentrations used here are sig-
nificantly above that value, and thus it is likely that Tet kills
cells in the biofilms, albeit rather inefficiently. We have there-
fore designed and used a variety of assays in order to evaluate
the antibacterial efficacy of electrospun Tet-loaded matrices
including: a 96-wellMTP biofilm assay, a colony biofilmmod-
el, and an ex vivo pig skin model.
Characterization of Electrospun Matrices of Zein
or Zein/PCL
The diameter of electrospun zein fibres (in triple layers, 3L)
was 0.99±0.36 μm (12). Electrospun zein/PCL fibres were
thicker than zein fibres and had more variability, with diam-
eter of 1.51±0.65 μm for zein/PCL (20:10) 3L. This can be
explained, in part, by the difference in viscosities displayed by
the polymeric solutions. The zein solution viscosity was 0.186
±0.012 Pa.s, whereas the zein/PCL solution viscosity was
much higher at 1.84±0.24 Pa.s. The increase in viscosity
may indicate a greater polymer chain entanglement in the
solution. Applying the same voltage to the more viscous
zein/PCL solution led to less jet stretching during the
electrospinning process, resulting in a larger fibre diameter.
Tet Release from Triple-Layered Matrices
Prior to release studies, the encapsulation efficiency of each
matrix formulation was determined with mats cut into small
discs (~6 mm diameter), weighed and then dissolved in
methanol:DCM (1:1 v/v, 10 mL). From the UV absorbance
(λ=360 nm, subtracting for zein absorbance at this wave-
length), the amount of Tet HCl in the fibres was then calcu-
lated using a Tet HCl calibration curve and subsequently
compared to the theoretical value (5%). Within experimental
error, encapsulation was quantitative for all but the zein/PCL
(20:10) 3L samples which had an encapsulation efficiency of
71±11% (12).
It is well known that light, temperature, moisture, and du-
ration of storage influence the stability of Tet leading to a
decrease in its microbiological activity and an increase in its
toxicity (29). The physical and chemical stability of Tet in
these electrospun zein matrices has therefore been examined
in detail (12). Following our recent precedent with electrospun
PCL matrices (29), we have applied 1H NMR spectroscopy
(Fig. 2) showing that the chemical integrity of loaded Tet HCl
was maintained after the electrospinning process as all the
signals of Tet HCl could be observed, comparable with the
literature data (29). We have also demonstrated spectroscopic
(UV) and spectrometric (MS) stability of electrospun Tet, and
employed Raman microscopy to demonstrate the even
distribution of Tet in the electrospun fibres (12). Signif-
icantly, we also show, vide infra, that the electrospun Tet
is still biologically active, working equally effectively in























Fig. 1 The activity of clinically used antibiotics (200 μL containing 50 μg/mL,
for 24 h) against preformed (24 h) MRSA252 biofilms (normalised relative to
crystal violet assayed biofilm formation in the absence of any antibiotic) tested
using the MTPmodel showing the efficiency of biofilm removal. The error bars
represent the standard deviation (n=3, in triplicate).
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In our previous in vitro study using electrospun zein (12), a
fast release of Tet from electrospun triple-layered zein (3L)
was observed within the first 3 h (47% of the encapsulated
drug). We have also previously shown that zein matrices
shrink in aqueous media and lose their fibrous structure
becoming a film (12) (Fig. 3). In order to overcome this, we
blended PCL with zein. This successfully maintained the fi-
brous structure on contact with water and stopped the
shrinkage (12) (Fig. 3). In addition, zein/PCL 3L showed a
more gradual release of Tet as only 19% was released within
the first 3 h. However, both formulations liberated 50% of the
encapsulated Tet after 24 h (Fig. 3). In the following days, zein
3L sustained the release of Tet up to 20 days in which a further
27% of encapsulated Tet was released.Whereas zein/PCL 3L
released a further 10% of Tet until day 15 when the release
plateaued. In the first few hours, zein/PCL 3L showed a bet-
ter gradual release than zein 3L, however, zein/PCL 3L re-
leased Tet in the following days very slowly compared to zein
3L. It is possible that the addition of PCL to the formulation
increased the hydrophobicity of the layered matrix and thus
restricted the water access to the drug encapsulated within the
polymeric blended fibres.
Effect of Matrices on Biofilms Measured in the MTP
Assay
The MTP assay has the advantage of being a simple, rapid,
and inexpensive screen of anti-biofilm agents using crystal
violet (19, 30). We modified the design of the assay in order
to investigate the antibacterial effect of sustained Tet release
and observed that 3L matrices significantly decreased the bio-
mass of biofilms formed by S. aureusMRSA252, and remained
bioactive when re-used on fresh biofilms (for three consecutive
days; more than 90% decrease, p<0.001; Fig. 4). Comparing
3L matrices to the Tet control results, Tet control decreased
the absorbance more than the triple matrices did in the first
48 h (p<0.05), while there was no significant difference after
72 h (p>0.05). This is due to the fact that a significant pro-
portion of the Tet load in the 3L matrices was encapsulated in
the polymeric fibrous matrices and not rapidly released.
Colony Biofilm Model (CBM)
In this model, biofilms were grown on a polycarbonate mem-
brane that sat on top of an agar plate in a system that mimics
Fig. 2 1H NMR spectra (CDCl3) of (in ascending order): Tet, Tet-free electrospun zein, electrospun zein matrix containing Tet, and electrospun zein containing
Tet but with the zein spectral data subtracted.
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biofilms growing in a wound (20, 22). The low fluid shear and
the proximity to an air interface provided by this model sim-
ulate the wound environment (31). Additionally, the nutrient
flow is similar to that of biofilms in a wound, with carbon and
nitrogen sources (usually from the host tissue in vivo) coming
from the agar, and the oxygen diffusing into the biofilm from
the air interface on the opposite side of the biofilm (20, 22, 31).
Figure 5 shows the antibacterial effectiveness of the formula-
tions. Compared with the control biofilms, the 3L matrices
significantly reduced the number of living cells in the biofilms
on the polycarbonate discs. The CFU/disc was reduced from
100% for untreated biofilms to ~35% for 3L matrices
(p<0.01). There was no significant difference in CFU/disc
achieved with zein 3L compared to zein/PCL 3L (p>0.05).
Ex Vivo Pig Skin Infection Model
Pig skin and human skin share many physiological and ana-
tomical similarities. For example, both pig and man have a
thick epidermis (50 to 120 μm in human compared to 30 to
140 μm in pigs). They both enjoy well-developed rete-ridges,
papillary bodies, and abundant subdermal adipose tissue.
They also demonstrate a similar size, orientation, and distri-
bution of blood vessels, adenexal structures, type of keratinous
proteins, collagen, body hair and lipid composition of the
stratum corneum (32). Here, an ex vivo pig skin model was used
to evaluate the antimicrobial efficacy of the 3L electrospun























zein 3L zein/PCL 3L
Fig. 3 The Tet release profile from the electrospun triple-layered electrospun matrices zein 3L and zein/PCL 3L with the Tet payload (5%) encapsulated in the
middle layer only. The error bars represent the standard deviation (n=3, in triplicate). The insets on the right show representative SEM images of electrospun zein
3L (upper) and electrospun zein/PCL (20:10) 3L (lower) matrices after immersion in PBS at 37°C (12). Below are other representative images showing, from the
left: electrospun zein 3L, electrospun zein 3L after immersion in PBS at 37°C, electrospun zein/PCL (20:10) after immersion in PBS at 37°C, and a fluorescence
























using the MTP model showing the
percentage of biofilm remaining
after treatment, where the
untreated biofilm acts as a control
for normalisation. The error bars
represent the standard deviation
(n=3, in triplicate).
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Figure 6 shows the antibacterial effectiveness of the formu-
lations against MRSA252 when grown on pig skin for 5 days
ex vivo. Compared with the untreated pig skin samples (as a
normalised control), the Tet loaded 3L matrices significantly
reduced the number of living cells; the CFU/skin sample was
reduced from 100% for untreated samples to 22% for com-
mercial Tet impregnated filter discs, 19% for zein/PCL 3L
matrices, and 10% for zein 3L matrices (all p<0.01). We did
note, however, that S. aureus MRSA252 did not grow partic-
ularly well on pig skin, and for that reason another S. aureus
strain, but a meticillin sensitive (MSSA) strain (ATCC 25923)
was also used. This strain grew significantly better on pig skin
and, similar to MRSA252, treating the infected pig skin with
Tet loaded zein/PCL 3L matrices also led to a significant
reduction in the number of CFU of ATCC 25923 (from
100±39% for the untreated sample to 27±4% for the treated
sample, p<0.01). Thus, these Tet loaded 3Lmatrices efficient-
ly killed both S. aureus MRSA252 and MSSA ATCC 25923
grown for 5 days on pig skin ex vivo and then treated with the
matrix formulation for 24 h.
Cell Viability Test (MTS Assay)
Having established in three different models of bacterial bio-
film formation that these electrospun fibrous 3L matrices are
releasing bioactive Tet in a sustained manner, we wanted to
show that this formulation is not toxic to human skin cells. The
3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-
2-(4-sulfophenyl)-2H-tetrazolium (MTS) assay was therefore
used to demonstrate that there was no adverse effect on the
growth of human primary skin fibroblast (FEK4) cells seeded
on zein/PCL+Tet electrospun fibrous matrices (single layer).
Commercially available Tet impregnated filter discs were
used as a control to investigate whether Tet is toxic to these
fibroblast cells or not. Figure 7 shows that the metabolic ac-
tivity of the cells 72 h after seeding on the zein/PCL+Tet
electrospun mats was similar to that of cells seeded on the
tissue culture plastic with or without the commercial Tet filter
discs (p>0.05), demonstrating that the zein/PCL blend, as a
biomaterial, supported fibroblast adhesion and growth, and
that the release of Tet from this formulation had no detrimen-
tal effect. This biocompatibility of soluble Tet with these cells
was confirmed by the observation that commercially available
Tet filter discs did not affect the growth of FEK4 cells on tissue
culture plastic (Fig. 7). These results, demonstrating the cellu-
lar compatibility of zein, are similar to the results within a
recent study examining the growth on murine fibroblasts on
zein nanofibres containing different concentrations of
curcumin (33). Therefore, these zein/PCL electrospun matri-
ces provide an attractive structure for the attachment and
growth of fibroblasts as cell culture surfaces and so they pres-
ent a suitable candidate for potential further applications in
drug delivery systems. Indeed, a related application on the
release of the antibiotic amoxicillin from electrospun fibrous

















Fig. 5 Effects of the Tet containing electrospun matrices on MRSA252
biofilms grown on polycarbonate discs tested using the CBM model






















Fig. 6 The antibacterial effects of Tet loaded formulations after 5 days of
incubating MRSA252 on pig skin, 37°C. The formulations were added on

















Cells + Tet disc
Cells + zein/PCL/Tet
Fig. 7 The MTS cell metabolism assay (normalised absorbance) demon-
strates the biocompatibility of zein/PCL+Tet, 72 h after seeding. The error
bars represent the standard deviation (n=3, in triplicate).
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CONCLUSIONS
The potential and feasibility of a blend of zein and PCL as a
drug delivery vehicle using designed and engineered
electrospun matrices has been investigated. As electrospun
Tet encapsulated zein fibres (i.e. zein without PCL) shrank
significantly in aqueous media, Tet encapsulated micro/
nanofibre zein/PCL 3L electrospun matrices were prepared,
where blending with PCL stopped the shrinkage (12). Tet
release was controlled for over 10 days demonstrating a po-
tential for application in wound treatments e.g. as dressings or
even as implants. In this paper, we demonstrate that this
sustained released Tet showed excellent antibiotic activity in
destroying preformed biofilms from S. aureus MRSA252 in
models resembling the situation found in wounds. In addition,
applying these Tet loaded matrices, for the first time, to ex vivo
pig skin models, growing either MRSA252 or ATCC 25923,
significantly reduced the bioburden of these clinically relevant
bacteria. These zein/PCL electrospun matrices were also
shown to be compatible with human fibroblast FEK4 skin
cells. Taken together, the clearly established ability of these
Tet loaded zein-based matrices to destroy bacteria within in-
creasingly complex in vitro and ex vivo biofilm models and their
biocompatibility with human skin cells lead to the conclusion
that these matrices could be well suited for applications in
wound healing and infection control.
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